Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis

J Hum Hypertens. 2011 Nov;25(11):699-702. doi: 10.1038/jhh.2011.36. Epub 2011 Apr 28.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / immunology
  • Arthritis, Rheumatoid / physiopathology
  • Blood Pressure / drug effects*
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / immunology
  • Endothelium, Vascular / physiopathology
  • England
  • Etanercept
  • Humans
  • Immunoglobulin G / therapeutic use
  • Inflammation Mediators / blood
  • Infliximab
  • Longitudinal Studies
  • Microvessels / drug effects*
  • Microvessels / immunology
  • Microvessels / physiopathology
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Time Factors
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Tumor Necrosis Factor-alpha / blood

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Immunoglobulin G
  • Inflammation Mediators
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Adalimumab
  • Etanercept